Real-world analysis of treatment sequencing and late-stage liquid biopsy genomic profiling in advanced pancreatic cancer

Abstract Background Real-world evidence on treatment sequencing and the molecular features of terminal-stage pancreatic cancer is limited. We evaluated treatment sequences and late-stage liquid biopsy genomic profiles using a nationwide clinico-genomic database. Methods We retrospectively analyzed 16,782 patients with pancreatic ductal adenocarcinoma registered in the Center for Cancer Genomics and Advanced Therapeutics database in Japan. Overall survival was compared according to first-line regimen and first- to second-line sequence. Liquid biopsy data were analyzed in relation to the time before death, and a gradient-boosting survival model was developed to identify prognostic genomic features. Results As first-line therapy, gemcitabine plus nab-paclitaxel was associated with longer overall survival than FOLFIRINOX (hazard ratio 0.89, 95% confidence interval 0.84–0.93), despite comparable time to treatment failure. Gemcitabine plus nab-paclitaxel followed by FOLFIRINOX was associated with the most favorable survival, measured from either first-line (hazard ratio 0.84) or second-line initiation (hazard ratio 0.68). Liquid biopsies were performed closer to death than tissue-based tests (median 140 vs. 473 days). The KRAS variant allele frequency increased as death approached and was the most influential prognostic feature; a KRAS -only model performed comparably to the full model (concordance index 0.67 for both), and survival worsened with increasing KRAS variant allele frequency. Alterations in chromatin-remodeling and epigenetic regulatory genes, including SMARCA4 , ARID1A , KDM6A , and KMT2D , were associated with poor prognosis. Conclusion Treatment sequencing may influence survival in advanced pancreatic cancer, and the KRAS variant allele frequency in late-stage liquid biopsy is a robust prognostic biomarker.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11496243/v1
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Real-world analysis of treatment sequencing and late-stage liquid biopsy genomic profiling in advanced pancreatic cancer

Eisuke Iwasaki, Naohiro Nishida, Okada Ken-ichi
Research Square
Pancreatic and Hepatic Oncology Research
preprint

Real-world analysis of treatment sequencing and late-stage liquid biopsy genomic profiling in advanced pancreatic cancer

Eisuke Iwasaki, Naohiro Nishida, Okada Ken-ichi
preprint en

Abstract

Abstract Background Real-world evidence on treatment sequencing and the molecular features of terminal-stage pancreatic cancer is limited. We evaluated treatment sequences and late-stage liquid biopsy genomic profiles using a nationwide clinico-genomic database. Methods We retrospectively analyzed 16,782 patients with pancreatic ductal adenocarcinoma registered in the Center for Cancer Genomics and Advanced Therapeutics database in Japan. Overall survival was compared according to first-line regimen and first- to second-line sequence. Liquid biopsy data were analyzed in relation to the time before death, and a gradient-boosting survival model was developed to identify prognostic genomic features. Results As first-line therapy, gemcitabine plus nab-paclitaxel was associated with longer overall survival than FOLFIRINOX (hazard ratio 0.89, 95% confidence interval 0.84–0.93), despite comparable time to treatment failure. Gemcitabine plus nab-paclitaxel followed by FOLFIRINOX was associated with the most favorable survival, measured from either first-line (hazard ratio 0.84) or second-line initiation (hazard ratio 0.68). Liquid biopsies were performed closer to death than tissue-based tests (median 140 vs. 473 days). The KRAS variant allele frequency increased as death approached and was the most influential prognostic feature; a KRAS -only model performed comparably to the full model (concordance index 0.67 for both), and survival worsened with increasing KRAS variant allele frequency. Alterations in chromatin-remodeling and epigenetic regulatory genes, including SMARCA4 , ARID1A , KDM6A , and KMT2D , were associated with poor prognosis. Conclusion Treatment sequencing may influence survival in advanced pancreatic cancer, and the KRAS variant allele frequency in late-stage liquid biopsy is a robust prognostic biomarker.

Research Square
Tokai University (JP)
Japan Society for the Promotion of Science
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon